UY39172A - Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e - Google Patents
Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis eInfo
- Publication number
- UY39172A UY39172A UY0001039172A UY39172A UY39172A UY 39172 A UY39172 A UY 39172A UY 0001039172 A UY0001039172 A UY 0001039172A UY 39172 A UY39172 A UY 39172A UY 39172 A UY39172 A UY 39172A
- Authority
- UY
- Uruguay
- Prior art keywords
- hepatitis
- treatment
- nucleoside analogues
- monocyclic nucleoside
- monocyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169480 | 2020-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39172A true UY39172A (es) | 2021-10-29 |
Family
ID=70289599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039172A UY39172A (es) | 2020-04-14 | 2021-04-13 | Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024086592A2 (en) * | 2022-10-17 | 2024-04-25 | Emory Unversity | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2025014360A1 (en) * | 2023-07-07 | 2025-01-16 | Erasmus University Medical Center Rotterdam | Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2952714T3 (es) * | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| US9603864B2 (en) * | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201610597QA (en) * | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2017210438A1 (en) * | 2016-06-03 | 2017-12-07 | Gilead Pharmasset Llc | Methods of treating hepatitis e viral infection |
-
2021
- 2021-04-13 KR KR1020227039015A patent/KR20230002592A/ko active Pending
- 2021-04-13 PE PE2022002242A patent/PE20230386A1/es unknown
- 2021-04-13 WO PCT/EP2021/059504 patent/WO2021209419A1/en not_active Ceased
- 2021-04-13 CN CN202180028212.9A patent/CN115515603A/zh active Pending
- 2021-04-13 AU AU2021255809A patent/AU2021255809B2/en active Active
- 2021-04-13 EP EP21716786.5A patent/EP4135715B1/en active Active
- 2021-04-13 CA CA3174790A patent/CA3174790A1/en active Pending
- 2021-04-13 JP JP2022562424A patent/JP2023522615A/ja active Pending
- 2021-04-13 AR ARP210100979A patent/AR121836A1/es unknown
- 2021-04-13 PH PH1/2022/552679A patent/PH12022552679A1/en unknown
- 2021-04-13 UY UY0001039172A patent/UY39172A/es unknown
- 2021-04-13 ES ES21716786T patent/ES2982564T3/es active Active
- 2021-04-13 MX MX2022012904A patent/MX2022012904A/es unknown
- 2021-04-13 BR BR112022020825A patent/BR112022020825A2/pt unknown
-
2022
- 2022-10-12 CL CL2022002804A patent/CL2022002804A1/es unknown
-
2026
- 2026-03-11 JP JP2026038584A patent/JP2026120528A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3174790A1 (en) | 2021-10-21 |
| US20230310481A1 (en) | 2023-10-05 |
| EP4135715A1 (en) | 2023-02-22 |
| CL2022002804A1 (es) | 2023-03-31 |
| AU2021255809B2 (en) | 2026-08-06 |
| CN115515603A (zh) | 2022-12-23 |
| PH12022552679A1 (en) | 2024-04-22 |
| BR112022020825A2 (pt) | 2022-11-29 |
| EP4135715B1 (en) | 2024-05-08 |
| ES2982564T3 (es) | 2024-10-16 |
| MX2022012904A (es) | 2023-01-24 |
| AU2021255809A1 (en) | 2022-12-15 |
| PE20230386A1 (es) | 2023-03-06 |
| EP4135715C0 (en) | 2024-05-08 |
| WO2021209419A1 (en) | 2021-10-21 |
| AR121836A1 (es) | 2022-07-13 |
| KR20230002592A (ko) | 2023-01-05 |
| JP2023522615A (ja) | 2023-05-31 |
| JP2026120528A (ja) | 2026-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000293A (es) | Análogos de nucleósido de 1-ciano y usos de los mismos | |
| CR20220236A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
| CL2020001146A1 (es) | Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
| UY38434A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) | |
| ECSP20029558A (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb) | |
| UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
| CO2020005420A2 (es) | Compuestos antibacterianos | |
| ECSP18061667A (es) | Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza | |
| CU24519B1 (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| ECSP21079317A (es) | Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| ECSP21031085A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| CO2024006727A2 (es) | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos | |
| CL2024003512A1 (es) | Compuestos antivirales derivados de indolinilo. | |
| CL2024000560A1 (es) | Inhibidores de indolina de kif18a | |
| DOP2018000183A (es) | Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos | |
| MX2022009176A (es) | Metodo y composiciones para el tratamiento de infeccion por coronavirus. | |
| CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
| BR112023001129A2 (pt) | Pró-fármacos antivirais, formulações farmacêuticas e métodos | |
| MX2023008004A (es) | Derivado de adenosina y composicion farmaceutica que lo comprende. | |
| CL2022002804A1 (es) | Análogos del nucleósido bicíclico y monocíclico para el tratamiento de la hepatitis e. | |
| CO2025018006A2 (es) | Formas sólidas de un inhibidor macrocíclico de farnesiltransferasa y formulaciones de estos, y métodos de preparación y uso del compuesto macrocíclico y sus formas sólidas | |
| BR112023016958A2 (pt) | Compostos para uso no tratamento de uma infecção por vírus envelopado | |
| UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
| BR112022020810A2 (pt) | Análogos de nucleosídeos espirocíclicos para o tratamento de hepatite e |